Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast CancerC. Domergue, Anne Patsouris, E. Martin et al.|Cancers|2022Cited by 67
156P Impact of HER2 status (HER2-low versus HER2-0) on complete histologic response after neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)C. Domergue, Anne Patsouris, Claude Lemarié et al.|Annals of Oncology|2021Cited by 3
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancerMarina Elena Cazzaniga, Maureen Trudeau, Foluso O. Ademuyiwa et al.|JNCI Cancer Spectrum|2023Cited by 3
774P Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME databaseM. Zenatri, Paule Augereau, E. Martin et al.|Annals of Oncology|2024Cited by 0